Prosecution Insights
Last updated: May 29, 2026

Examiner: SMALL, KATHERINE R

Tech Center 1600 • Art Units: 1633

This examiner grants 65% of resolved cases

Performance Statistics

65.4%
Allow Rate
+5.4% vs TC avg
77
Total Applications
+29.7%
Interview Lift
1379
Avg Prosecution Days
Based on 52 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
15.9%
§102 Novelty
77.2%
§103 Obviousness
4.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17273999 NUCLEIC ACID ASSEMBLIES FOR USE IN TARGETED DELIVERY Final Rejection Massachusetts Institute of Technology
18015158 Improving Packed Red Blood Cell Storage with a High Viscosity Buffered Storage Solution Non-Final OA University of Cincinnati
17593085 METHODS FOR PRODUCTION OF CAR-NK CELLS AND USE THEREOF Non-Final OA Board of Regents, The University of Texas System
17927637 COMBINATION CYTOKINES FOR METHODS AND COMPOSITIONS FOR TREATING CANCER Final Rejection UNIVERSITY HEALTH NETWORK
17430541 COMPOSITIONS AND METHODS FOR STEM CELL THERAPY Non-Final OA University of Houston System
17271902 METHOD FOR EVALUATING ANTI-INFECTIVE DRUGS, VACCINES, ETC. USING IMMORTALIZED MONOCYTIC CELLS AND INDUCED CELLS Final Rejection OSAKA UNIVERSITY
18037945 LIGHT-CONTROLLED VIRAL TRANSDUCTION Non-Final OA ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
17738584 INDUCTION OF TUMOR VASCULAR NECROSIS UTILIZING FIBROBLASTS Non-Final OA FibroBiologics
17603276 Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins Final Rejection Nature's Toolbox, Inc.
17761565 BONE MARROW MESENCHYMAL STEM CELL DERIVED CELL POPULATIONS AND METHODS OF PREPARING SAME Final Rejection THE UNIVERSITY OF LIVERPOOL
18028029 VIRAL VECTORS AND USES THEREOF Non-Final OA SUNSHINE LAKE PHARMA CO., LTD.
17293797 FUSOSOME COMPOSITIONS FOR HEMATOPOIETIC STEM CELL DELIVERY Final Rejection FLAGSHIP PIONEERING INNOVATIONS V, INC.
17312783 METHODS OF MANUFACTURING CELL BASED PRODUCTS USING SMALL VOLUME PERFUSION PROCESSES Non-Final OA ERBI BIOSYSTEMS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month